SCHEMBL3395963

SCHEMBL3395963

NC(=S)Cc1cccc(Cl)c1Cl

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.74
PNMT P11086 2/20 0.59
TAAR1 Q96RJ0 3/20 0.53
IDO1 P14902 5/20 0.52
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.41
DBH P09172 1/20 0.40
CYP2A13 Q16696 1/20 0.40
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3714040 0.85 PKM (1.00) PKMPNMTTAAR1IDO1ALDH1A1
SCHEMBL8818480 0.81 PNMT (0.56) PKMPNMTTAAR1IDO1GRIN1
SCHEMBL30899396 0.79 PNMT (0.59) PKMPNMTTAAR1IDO1GRIN1
SCHEMBL3393837 0.79 PNMT (0.59) PKMPNMTTAAR1IDO1GRIN1
SCHEMBL29760897 0.79 PNMT (0.59) PKMPNMTTAAR1IDO1GRIN1
SCHEMBL8238578 0.79 PNMT (0.59) PKMPNMTTAAR1IDO1GRIN1
SCHEMBL4276985 0.78 PKM (0.61) PKMPNMTTAAR1IDO1ALDH1A1
Hydrochloric Acid SCHEMBL15863064 0.78 PNMT (0.57) PKMPNMTTAAR1IDO1GRIN1
SCHEMBL27580277 0.77 PNMT (0.52) PKMPNMTTAAR1IDO1ALDH1A1
SCHEMBL9629915 0.77 PKM (0.71) PKMTAAR1IDO1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 PKM 3897/4885PNMT 2060/4885TAAR1 4601/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 PKM 3897/4885PNMT 2060/4885TAAR1 4601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.